Ameriprise’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$247M Buy
319,677
+27,758
+10% +$21.3M 0.06% 324
2025
Q4
$226M Buy
291,919
+8,814
+3% +$5.99M 0.05% 342
2025
Q3
$159M Sell
283,105
-4,594
-2% -$2.6M 0.04% 422
2025
Q2
$152M Sell
287,699
-52,446
-15% -$29.3M 0.04% 427
2025
Q1
$216M Buy
340,145
+13,594
+4% +$9.35M 0.06% 313
2024
Q4
$232M Sell
326,551
-40,208
-11% -$33.7M 0.06% 302
2024
Q3
$386M Sell
366,759
-8,119
-2% -$9.04M 0.1% 215
2024
Q2
$395M Buy
374,878
+42,333
+13% +$41M 0.11% 202
2024
Q1
$320M Sell
332,545
-3,306
-1% -$3.14M 0.09% 239
2023
Q4
$295M Sell
335,851
-29,823
-8% -$24.6M 0.09% 239
2023
Q3
$301M Sell
365,674
-10,854
-3% -$8.53M 0.1% 210
2023
Q2
$271M Buy
376,528
+18,580
+5% +$14.3M 0.08% 244
2023
Q1
$294M Buy
357,948
+22,584
+7% +$17M 0.1% 223
2022
Q4
$242M Buy
335,364
+39,864
+13% +$29.4M 0.08% 249
2022
Q3
$204M Sell
295,500
-12,936
-4% -$8.14M 0.08% 271
2022
Q2
$182M Sell
308,436
-90,395
-23% -$58.8M 0.06% 311
2022
Q1
$278M Sell
398,831
-8,165
-2% -$5.17M 0.08% 255
2021
Q4
$257M Buy
406,996
+26,327
+7% +$16.2M 0.07% 290
2021
Q3
$230M Sell
380,669
-30,628
-7% -$19M 0.07% 287
2021
Q2
$230M Buy
411,297
+126,731
+45% +$64.2M 0.07% 292
2021
Q1
$135M Buy
284,566
+11,724
+4% +$5.71M 0.04% 400
2020
Q4
$132M Sell
272,842
-3,764
-1% -$2.03M 0.05% 401
2020
Q3
$155M Buy
276,606
+4,209
+2% +$2.55M 0.06% 306
2020
Q2
$170M Sell
272,397
-16,695
-6% -$9.48M 0.07% 266
2020
Q1
$141M Sell
289,092
-27,220
-9% -$11.2M 0.07% 259
2019
Q4
$119M Buy
316,312
+632
+0.2% +$213K 0.05% 350
2019
Q3
$87.6M Buy
315,680
+26,733
+9% +$7.91M 0.04% 449
2019
Q2
$90.4M Buy
288,947
+3,198
+1% +$1.06M 0.04% 454
2019
Q1
$117M Sell
285,749
-12,556
-4% -$5.17M 0.05% 351
2018
Q4
$111M Buy
298,305
+1,128
+0.4% +$413K 0.06% 341
2018
Q3
$120M Sell
297,177
-18,346
-6% -$6.98M 0.04% 395
2018
Q2
$109M Buy
315,523
+36,669
+13% +$11.5M 0.05% 387
2018
Q1
$96M Buy
278,854
+30,853
+12% +$10.7M 0.04% 395
2017
Q4
$93.2M Buy
248,001
+28,984
+13% +$11.7M 0.04% 394
2017
Q3
$97.9M Buy
219,017
+1,809
+0.8% +$861K 0.05% 374
2017
Q2
$107M Sell
217,208
-60,850
-22% -$26.6M 0.05% 335
2017
Q1
$108M Sell
278,058
-74,762
-21% -$27.7M 0.06% 329
2016
Q4
$130M Buy
352,820
+79,810
+29% +$30.3M 0.07% 285
2016
Q3
$110M Buy
273,010
+196,415
+256% +$78.8M 0.06% 318
2016
Q2
$26.7M Buy
76,595
+41,590
+119% +$16M 0.02% 756
2016
Q1
$12.6M Sell
35,005
-57,581
-62% -$23.7M 0.01% 1244
2015
Q4
$50.6M Sell
92,586
-84,515
-48% -$45.8M 0.03% 471
2015
Q3
$82.4M Buy
177,101
+94,614
+115% +$50.8M 0.05% 332
2015
Q2
$42.1M Buy
82,487
+1,420
+2% +$693K 0.02% 596
2015
Q1
$36.6M Buy
81,067
+47,103
+139% +$20M 0.02% 656
2014
Q4
$13.9M Buy
33,964
+1,735
+5% +$682K 0.01% 1224
2014
Q3
$11.6M Sell
32,229
-1,291
-4% -$433K 0.01% 1340
2014
Q2
$9.47M Buy
33,520
+584
+2% +$173K 0.01% 1583
2014
Q1
$9.89M Sell
32,936
-39,530
-55% -$12.2M 0.01% 1531
2013
Q4
$19.9M Sell
72,466
-111,360
-61% -$32M 0.01% 995
2013
Q3
$57.5M Buy
183,826
+45,813
+33% +$12.1M 0.04% 488
2013
Q2
$31M Buy
+138,013
New +$32.1M 0.02% 733

Other funds holding REGN

Ameriprise's REGN Position: Q1 2026 in Review

Ameriprise increased its Regeneron Pharmaceuticals (REGN) stake by 9.5% in Q1 2026, buying an estimated $21.3M and bringing the position to 319,677 shares worth $247M. The position accounts for 0.06% of the portfolio, ranked #324.

Ameriprise first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $395M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Ameriprise held 319,677 shares of Regeneron Pharmaceuticals worth $247M as of Q1 2026.
  • Ameriprise bought 27,758 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $21.3M.
  • Regeneron Pharmaceuticals made up 0.06% of Ameriprise's portfolio in Q1 2026, its #324 holding.
  • Ameriprise first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Ameriprise's Regeneron Pharmaceuticals position peaked at $395M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.